@article{f0362159b23f4c988b36c68218361099,
title = "Exhaled nitric oxide (FeNO): Bridging a knowledge gap in asthma diagnosis and treatment",
keywords = "FeNO, asthma, biomarkers, exacerbations",
author = "Celis-Preciado, \{Carlos Andr{\'e}s\} and Philippe Lachapelle and Simon Couillard",
note = "Funding Information: Carlos Andr{\'e}s Celis-Preciado: reports speaker honoraria from AstraZeneca, GlaxoSmithKline and Sanofi-Regeneron; he received consultancy fees from AstraZeneca, GlaxoSmithKline and Sanofi-Regeneron. Philippe Lachapelle reports speaker honoraria from AstraZeneca, Sanofi-Regeneron, GlaxoSmithKline, Boehringer Ingelheim and Novartis outside of the submitted work; he received consultancy fees from AstraZeneca, GlaxoSmithKline and Sanofi-Regeneron. Simon Couillard reports non-restricted research grants from the NIHR Oxford BRC, the Quebec Respiratory Health Research Network, the Fondation Qu{\'e}b{\`e}coise en Sant{\'e} Respiratoire, AstraZeneca, bioM{\'e}rieux and Sanofi-Genyme-Regeneron; he is the holder of the Association Pulmonaire du Qu{\'e}bec's Research Chair in Respiratory medicine and is a Clinical research scholar of the Fonds de recherche du Qu{\'e}bec; he received speaker honoraria from AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron and Valeo Pharma; he received consultancy fees for FirstThought, AstraZeneca, GlaxoSmithKline and Sanofi-Regeneron; he has received sponsorship to attend/speak at international scientific meetings by/for AstraZeneca and Sanofi-Regeneron. He is an advisory board member and will have stock options for Biometry Inc—a company developing a FeNO device (myBiometry). He advised the Institut national d'excellence en sant{\'e} et services sociaux (INESSS) for an update of the asthma general practice information booklet for general practitioners. Supported by the Association Pulmonaire du Qu{\'e}bec and the Fonds de Recherche du Qu{\'e}bec. Funding Information: Carlos Andr{\'e}s Celis‐Preciado: reports speaker honoraria from AstraZeneca, GlaxoSmithKline and Sanofi‐Regeneron; he received consultancy fees from AstraZeneca, GlaxoSmithKline and Sanofi‐Regeneron. Philippe Lachapelle reports speaker honoraria from AstraZeneca, Sanofi‐Regeneron, GlaxoSmithKline, Boehringer Ingelheim and Novartis outside of the submitted work; he received consultancy fees from AstraZeneca, GlaxoSmithKline and Sanofi‐Regeneron. Simon Couillard reports non‐restricted research grants from the NIHR Oxford BRC, the Quebec Respiratory Health Research Network, the Fondation Qu{\'e}b{\`e}coise en Sant{\'e} Respiratoire, AstraZeneca, bioM{\'e}rieux and Sanofi‐Genyme‐Regeneron; he is the holder of the Association Pulmonaire du Qu{\'e}bec's Research Chair in Respiratory medicine and is a Clinical research scholar of the Fonds de recherche du Qu{\'e}bec; he received speaker honoraria from AstraZeneca, GlaxoSmithKline, Sanofi‐Regeneron and Valeo Pharma; he received consultancy fees for FirstThought, AstraZeneca, GlaxoSmithKline and Sanofi‐Regeneron; he has received sponsorship to attend/speak at international scientific meetings by/for AstraZeneca and Sanofi‐Regeneron. He is an advisory board member and will have stock options for Biometry Inc—a company developing a FeNO device (myBiometry). He advised the Institut national d'excellence en sant{\'e} et services sociaux (INESSS) for an update of the asthma general practice information booklet for general practitioners. Funding Information: Supported by the Association Pulmonaire du Qu{\'e}bec and the Fonds de Recherche du Qu{\'e}bec. ",
year = "2023",
month = aug,
doi = "10.1111/cea.14374",
language = "English",
volume = "53",
pages = "791--793",
journal = "Clinical and Experimental Allergy",
issn = "0954-7894",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "8",
}